Phase II Study of Irinotecan in Combination with Capecitabine on a 3-Weekly Schedule as First-Line Chemotherapy for Patients with Metastatic or Locally Advanced Colorectal Cancer. J. Anal. Oncol. 2013;2(3): 151-159. doi:10.6000/1927-7229.2013.02.03.4